Dr Vinita Jagannath (Merck & Co., Inc., NJ, USA) presented results from the phase 3 trial STRIDE-13 (NCT06177912), a randomised, controlled, double-blind study comparing V116 with PPSV23. Participants were children and adolescents aged ≥2 to <18 years who had completed primary pneumococcal vaccination and were considered at risk due to underlying medical conditions. Endpoints included safety, non-inferiority of V116 to PPSV23 for 12 common serotypes (3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, 33F) and superiority for 9 serotypes unique to V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, 35B) assessed by opsonophagocytic activity at 30 days post-vaccination. In total, 531 participants received V116 and 351 received PPSV23 [1].
Vaccine-related injection-site adverse events (AEs) were more common with V116 than with PPSV23 (72.5% vs 58.2%), but vaccine-related systemic AEs occurred at similar rates (43.8% vs 40.6%). Solicited AEs were generally comparable between groups, except for injection-site pain (67.7% vs 54.5%) and erythema (24.3% vs 16.4%), which were more frequent with V116.
At 30 days post-vaccination, V116 was non-inferior to PPSV23 for all 12 common serotypes (see Figure) and met the criteria for superiority for the 9 serotypes unique to V116.
Figure. Serotype-specific OPA GMT ratios for common serotypes [1]
CI, confidence interval; OPA, opsonophagocytic activity; GMT, geometric mean titre.
“In children and adolescents, V116 is well tolerated, with a safety profile generally comparable to that of PPSV23”, concluded Dr Jagannath. “V116 elicits robust immune responses to all 21 serotypes included in the vaccine and met the predefined non-inferiority criteria. Therefore, it has the potential to broaden coverage in children and adolescents at risk of pneumococcal disease.”
- Jagannath V, et al. A Phase 3, Randomised, double-blind study to evaluate safety and immunogenicity of V116, a pneumococcal conjugate vaccine, in children and adolescents with increased risk of pneumococcal disease (STRIDE-013). 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.
Copyright ©2025 Medicom Publishing Group
Posted on
Table of Contents: ESCMID Vaccines 2025
Featured articles
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
Pneumococcal Vaccination
A quarter of US children have incomplete pneumococcal vaccination by age 2
V116 shows promise for adults at risk of pneumococcal disease
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease
Influenza and COVID-19 Vaccination
Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals
Intranasal COVID-19 vaccine shows promising results in preclinical mouse models
Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season
Lower age is linked to reduced uptake of influenza and COVID-19 vaccination
RSV vaccination and Immunisation
Combination respiratory vaccines show promise but face key challenges
Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA
RSV immunisation: Maternal versus direct infant immunisation
European pregnant women show openness to maternal RSV vaccination
Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation
Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years
Other Childhood and Routine Vaccinations
Pertussis vaccination: Could an intranasal vaccine help curb the rising cases of whooping cough?
Does the 2+1 vaccination schedule for Haemophilus influenzae type b increase case numbers?
Wastewater poliovirus detections in Europe may reflect seasonal infection patterns rather than consistent importation
Emerging and Future Vaccines
Where do we stand with vaccination for haemolytic streptococci?
The future looks promising for tuberculosis vaccination
Where do alternative vaccine administration routes fit in the clinical landscape?
Malaria immunisation beyond subunit vaccines: Current progress
SARI Definitions and Vaccine Effectiveness
Case definition discrepancies influence VE outcomes
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com